A clinical trial study, published in the Lancet Diabetes and Endocrinology, revealed that certain diabetic drugs are linked to heart failure. The study analyzed more than 95,000 patients from fourteen trials.
The data obtained from these patients was analyzed to calculate the relative risks of heart failure posed by each type 2 diabetes treatment methodology. The results reflect that there was a 14% increased risk of heart failure in patients who where on sugar lowering drugs to manage diabetes.
Heart failure affects approximately 5.1 million people in the US and is characterized by breathlessness, tiredness and swollen ankles.
The researchers attributed the increased risk of heart failure directly to the type of diabetes therapy that was chosen, with some drugs more likely to cause heart failure than others, compared with placebo or standard care. In general it was revealed that for every kilo of weight gain due to sugar-lowering diabetes treatment, there was an associated 7% higher risk of heart failure directly linked to that treatment. For every 200 patients treated, there was one extra hospital admission for heart failure after an average follow-up of 4 years.
Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials, Jacob A Udell, et al., Lancet Diabetes Endocrinol., doi:10.1016/S2213-8587(15)00044-3, published online 16 March 2015, abstract.